Voloridge Investment Management
NRIX icon

Voloridge Investment Management’s Nurix Therapeutics NRIX Stock Holding History

Voloridge Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-154,459
Closed -$2.93M – 1190
2025
Q4 		$2.93M Buy
154,459
+5,318
+4% +$76.4K 0.01% 863
2025
Q3 		$1.38M Sell
149,141
-225,709
-60% -$2.34M ﹤0.01% 991
2025
Q2 		$4.27M Buy
374,850
+195,730
+109% +$2.12M 0.02% 792
2025
Q1 		$2.13M Buy
+179,120
New +$3M 0.01% 952
2024
Q4 		– Sell
-241,048
Closed -$5.42M – 1307
2024
Q3 		$5.42M Sell
241,048
-93,924
-28% -$2.13M 0.02% 758
2024
Q2 		$6.99M Buy
+334,972
New +$5.22M 0.03% 661
2022
Q4 		– Sell
-75,876
Closed -$989K – 1574
2022
Q3 		$989K Buy
+75,876
New +$1.2M 0.01% 1165
2021
Q3 		– Sell
-106,320
Closed -$2.82M – 1791
2021
Q2 		$2.82M Buy
106,320
+42,968
+68% +$1.26M 0.02% 861
2021
Q1 		$1.97M Buy
+63,352
New +$2.4M 0.01% 831

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Voloridge Investment Management's NRIX Position: Q1 2026 in Review

Voloridge Investment Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 154,459 shares — an estimated $2.93M sold.

Voloridge Investment Management first reported a position in NRIX in Q1 2021 and held it in 9 quarters. The position peaked at $6.99M in Q2 2024. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Voloridge Investment Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 154,459 Nurix Therapeutics shares in Q1 2026, an estimated $2.93M.
  • Voloridge Investment Management first reported a position in Nurix Therapeutics in Q1 2021 and held it in 9 quarters.
  • Voloridge Investment Management's Nurix Therapeutics position peaked at $6.99M in Q2 2024.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.